Public Policy
PHARMACEUTICALS
01/01/2017
(RESOLUTION 16-29) RESOLVED, that the ISMA seek pharmacy board regulation or, if necessary, legislation and involve other interested parties to require locations that dispense medications to have a mechanism for patients to return unused medications; and be it further RESOLVED, that such disposal shall be at no additional cost or significant inconvenience to the patient. (RESOLUTION 16-28) RESOLVED, that the ISMA support appropriate laws and/or policy to be propagated to assure that physicians are routinely notified of narcotic overdose or death of patients for whom they have prescribed narcotics in the preceding six months. (RESOLUTION 15-25) RESOLVED, that the ISMA House of Delegates work with the governor, legislature, or appropriate state agencies to review the structure and function of the Indiana State Board of Accounts with the goal of improving the board such that its recommendations are more practical and workable, while promoting accurate accounting and decreasing the risk of loss. (RESOLUTION 14-30) RESOLVED, that short-term urgent refills should be allowed once a month for certain critical medications when authorization is not readily available after hours, on weekends and on holidays, and that this recommendation be sent to the Food and Drug Administration and other vested parties, and ask that the same parties generate a list of critical medications qualifying for a five-day urgent refill; and be it further RESOLVED, that the AMA generate model state legislation to allow short-term urgent refills for certain critical medications as often as once a month. (RESOLUTION 13-32) RESOLVED, that the ISMA seek regulation or legislation requiring insulin to be available by prescription, and be it further RESOLVED, that the ISMA delegation as the AMA to seek federal regulation or legislation requiring insulin be available by prescription and to encourage individual states to seek regulations or legislation requiring prescriptions for insulin.  (RESOLUTION 13-24) RESOLVED, that the ISMA support the “Prescribers Toolkit” concepts published by the Office of Indiana Attorney General Indiana Prescription Drug Abuse Prevention Task Force and its subcommittee on education. (RESOLUTION 13-17) RESOLVED, that the ISMA membership endorse emergency rules addressing responsible opioid prescribing as proposed by the ISMA, the Office of the Indiana Attorney General, the American Association of Pain Management and other stakeholders. (RESOLUTION 13-03) RESOLVED, that the ISMA support legislation in the Indiana General Assembly to include tramadol as a Class IV controlled substance. (RESOLUTION 11-40) RESOLVED, that the AMA promote policies to prevent fraudulent prescriptions, such as by having the pharmacy notify the “prescribing” physician each time a controlled substance is dispensed or by assigning physicians a unique code number that must accompany each controlled prescription. This code number would be changed periodically; and be it further, RESOLVED, that the AMA promote and facilitate the establishment of controlled substances tracking programs in all states, the free exchange of controlled substance prescription data between all states, and the tracking of all controlled substance classes; and be it further, RESOLVED, that the AMA promote and facilitate a change of federal rules and regulations such that methadone clinics would report methadone dispensed for outpatient use to their appropriate state-controlled substance prescription tracking program; and be it further, RESOLVED, the AMA encourage the Veterans Administration and Department of Defense facilities to report outpatient controlled substance prescriptions to their appropriate state-controlled substance prescription tracking program; and be it further, RESOLVED, that the AMA promote and facilitate rules and regulations in all states that require reporting of veterinarian-controlled substance prescriptions with the prescription assigned to the owner of the animal and the individual who picks up the prescription; and be it further, RESOLVED, that the AMA encourage states to require hospital pharmacies to report outpatient controlled substance prescriptions to the appropriate tracking program; and be it further, RESOLVED, that the AMA encourage states to publicize their controlled substances prescription data for the edification of the public and drug policy makers; and be it further, RESOLVED, that the AMA maintain its important role for physicians by: 1) promoting physician training and competence on the proper use of controlled substances; 2) encouraging physicians to use screening tools (such as NIDAMED) for drug use in their patients; 3) providing references and resources for physicians so they identify and promote treatment for unhealthy behaviors before they become life-threatening; 4) encouraging physicians to use opiate and other controlled substances contracts with their patients; and 5) encouraging physicians to query their state's controlled substances databases for information on their patients on controlled substances; and be it further, RESOLVED, that this resolution (11-40) will be sent to the AMA for discussion and consideration if adopted by the ISMA House of Delegates. (RESOLUTION 11-34) RESOLVED, that the ISMA support a legislative and/or administrative remedy that requires all pharmacies to provide their pharmacists access to the Indiana INSPECT program website; and be it further, RESOLVED, that the ISMA continue to educate and encourage physicians and other providers to use the INSPECT program to review controlled substances prescription histories of their patients who are prescribed controlled substances. (READOPTED 10-64, HOD; RESOLUTION 00-37) RESOLVED, that the ISMA continue to support the concept of a voluntary regional drug depository; and be it further, RESOLVED, that the ISMA educate its membership and other interested parties about the concept of a voluntary regional drug depository. (RESOLUTION 10-14) RESOLVED, that the ISMA work with the appropriate state and federal agencies to modify INSPECT so that individual physicians can query, but not be required to query, their individual DEA numbers and see what prescriptions have been filled by whom under their prescribing authority. (READOPTED 09-60, HOD; RESOLUTION 99-51) RESOLVED, that the ISMA support or initiate legislation to change the present requirements governing the providing of prescription medication (not controlled substances) that would allow free or reduced fee health care facilities the opportunity to provide pharmaceutical services. (READOPTED 09-53, HOD; READOPTED 99, HOD; RESOLUTION 86-27) RESOLVED, that the ISMA completely and officially oppose the use of anabolic steroids for nonmedical use. (READOPTED 09-52, HOD; READOPTED 99, HOD; RESOLUTION 87-18) RESOLVED, that the ISMA oppose any legislative or regulatory attempts that would deny the physician the legal and professional right to dispense medications from the office, and that the ISMA would continue to keep its members informed about the proper guidelines and procedures for dispensing medications from the office. (READOPTED 09-51, HOD; READOPTED 99, HOD; RESOLUTION 89-18) RESOLVED, that the ISMA endorse the concept of a drug-free Indiana and lend its support and expertise to attain this goal when asked to participate. (READOPTED 09-46, HOD; READOPTED 99, HOD; RESOLUTION 76-1) RESOLVED, that the ISMA oppose generic substitution for a prescribed drug done at the discretion of a pharmacist. (RESOLUTION 08-31A) RESOLVED, that the ISMA support the Indiana Pharmacists Alliance's development of a system that will accommodate the needs of patients who present with a legally written prescription or request a non-prescription drug that is required to be stored behind the pharmacy counter. (RESOLUTION 08-25) RESOLVED, that the ISMA collaborate with other agencies and organizations to educate Hoosiers about prescription medicine abuse; and be it further, RESOLVED, that the ISMA inform Hoosier physicians of the magnitude of prescription medicine abuse with helpful hints to reduce abuse, such as talking to patients about the handling and safe-keeping of drugs, using INSPECT, etc.; and be it further, RESOLVED, that the ISMA collaborate with pharmacists, pharmacies and pharmaceutical companies and organizations to reduce prescription medicine abuse; and be it further, RESOLVED, that the ISMA study the role of prescription medicine abuse from Internet sales and report to the 2009 ISMA House of Delegates via resolution/report if appropriate. (RESOLUTION 08-19) RESOLVED, that the ISMA seek legislation to require the Medicaid program and private insurance companies to use electronic drug formularies and to provide financial incentives to encourage the use of e-prescribing by physicians. (RESOLUTION 07-04) RESOLVED, that the ISMA support full disclosure by all participants who formulate clinical practice guidelines of their relationships with pharmaceutical and medical device industries. (1/21/98, BOT) Reaffirmed support for the current generic substitution statute. (1/17/96, BOT) Approved not opposing the following policy regarding pharmacists: That drug therapy management should be limited to acute care hospitals. Pharmacists should not manage hyperalimentation. Drug therapy management may occur only when the physician acts to allow it. (4/10/88, BOT) Registered opposition to the multiple copy prescription program; but if the program goes into effect, the 10 recommendations, as outlined in the April 10 "Suggested Report" from the ISMA Department of Government Relations, be submitted to the Education Forum Subcommittee, the Prescription Pad Subcom­mittee, as well as the Prescription Abuse Study Committee for consideration. (1/17/88, BOT) Approved the restriction of amphetamine use in that Schedule II not be used for weight control and that Schedules III and IV (anorectic) be limited in their use, to be determined by the Indiana Medical Licensing Board.
Legislative News Articles
Licensing [02/27/2017]
Licensing [02/27/2017]
Licensing [02/27/2017]
Licensing [02/27/2017]
Licensing [02/27/2017]
Insurance [02/27/2017]
Pharmacy [02/27/2017]
Pharmacy [02/27/2017]
Miscellaneous [02/27/2017]
Public Health [02/27/2017]
Prescribing [02/27/2017]
Prescribing [02/27/2017]
Prescribing [02/27/2017]
Prescribing [02/27/2017]
Introduction [02/27/2017]